MiRNA-155 can directly target FOXO3a and decrease its expression, which results in breast cancer cells acquiring resistance to a variety of chemotherapy drugs, including DOX, etoposide (VP-16), and PTX [36]. Here, FOXO3 is linked to breast carcinoma.